Strong Association of CTLA-4 Variation (CT60A/G) and CTLA-4 Haplotypes with Predisposition of Iranians to Head and Neck Cancer
(ندگان)پدیدآور
Erfani, NasrollahHaghshenas, Mohammad RezaHoseini, Mohammad AliHashemi, Seyed BasiKhademi, BijanGhaderi, Abbas
نوع مدرک
TextOriginal Article
زبان مدرک
Englishچکیده
Background: Variations in Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) affect the expression and function of this protein. Objective: We aimed to investigate the association of +49 A/G (rs231775), +1822 C/T (rs231779) and +6230 A/G (CT60, rs3087243) genetic variations, as well as the merged haplotypes in CTLA-4 gene with susceptibility to, or progression of head and neck cancer. Methods: Eighty patients with confirmed head and neck (HN) cancer (age 54.9 ± 16.1 years) and 85 healthy age/sexmatched controls (age 56.3 ± 12.4 years) were enrolled in the study. Genotypes were investigated by the PCR-RFLP method. Arlequin software package was used to check for Hardy-Weinberg equilibration, and to estimate the haplotypes. Results: At position +6230 A/G (CT60), AA genotype, as well as A allele was significantly decreased in patients with HN cancers than controls (18.8% vs. 40.7%, p=0.004; odds ratio=0.34, and 46.3% vs. 61.7, p=0.007; odds ratio=0.53%, respectively). Nearly the same results were obtained when we compared the subgroup of patients with squamous cell carcinoma of the HN (SCC-HN) with control subjects. The frequencies of genotypes and alleles at other positions were not significantly different between patients and controls, however ACG, GTA and GCA haplotypes emerged from three investigated loci occurred with significantly more frequencies in patients (pConclusion: Our results suggest that CT60 A allele, as well as ACA and GTG haplotypes in CTLA-4 gene may have protective roles against HN cancer in Iranian population, while ACG, GTA and specially GCA haplotypes may render susceptibility.
کلید واژگان
Genetic Markerctla-4
Haplotype
Head and Neck Cancer
Polymorphism
Squamous cell carcinoma
شماره نشریه
3تاریخ نشر
2012-09-011391-06-11
ناشر
Shiraz Institute for Cancer Researchسازمان پدید آورنده
Cancer Immunology Group, Shiraz Institute for Cancer ResearchCancer Immunology Group, Shiraz Institute for Cancer Research
Department of Otolaryngology-Head and Neck Surgery, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Otolaryngology-Head and Neck Surgery, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Otolaryngology-Head and Neck Surgery, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Cancer Immunology Group, Shiraz Institute for Cancer Research
شاپا
1735-13831735-367X



